Medical/Pharmaceuticals News & Press Release Distribution

Satisfai Health acquires global license for AI software to detect early cancer in Barrett's Esophagus

Advanced real-time clinical diagnostics for up to 150 million people VANCOUVER, BC, Sept. 16, 2021 /PRNewswire/ -- Satisfai Health, a leading medical solutions provider specializing in artificial intelligence (AI) applications, particularly in Gastrointestinal Endoscopy, has acquired an exclusiv...

2021-09-16 22:17 4053

Validic Empowers Physicians and Care Managers to Manage Personal Health Data at Scale

Validic's best-in-class strategy is supported by its deep integration into clinical workflows and care pathways and its simple application design for consumer engagement SANTA CLARA, Calif., Sept. 16, 2021 /PRNewswire/ -- Based on its recent analysis of the North American remote patient monitori...

2021-09-16 21:00 2559

COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients

TAIPEI, Sept.16, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its oral investigational new drug Antroquinonol (HOCENA®) has made headway withCOVID-19 treatment development in more broaden clinical ...

2021-09-16 18:05 2761

COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients

Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress

SHANGHAI and WARREN, New Jersey, Sept. 16, 2021 /PRNewswire/ -- Laekna Therapeutics, an emerging innovative biotech company based inChina's "Zhangjiang Pharma Valley" andNew Jersey, USA, focusing on the development of ground-breaking innovative therapies to treat cancer and liver diseases, repor...

2021-09-16 17:06 1977

Beyond Ventures' first investment, Prenetics, becomes first Hong Kong unicorn to go public

HONG KONG, Sept. 16, 2021 /PRNewswire/ -- Hong Kong-based venture capital firm Beyond Ventures is pleased to support today's announcement by the firm's first investee company, Prenetics, that Prenetics, a global leader in genomic and diagnostic testing is set to merge with Artisan Acquisition Cor...

2021-09-16 15:31 2821

GeneQuantum announces two key leadership appointments

SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry-leading biotech company dedicated to the next generation bioconjugate drugs based on the innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced the appointment of Dr.Li Wan as the ...

2021-09-16 09:00 1959

SuperTrans Medical supported by U.S. National Institutes of Health (NIH) in developing its lead antibiotic against urgent threat drug resistant bacteria

SYDNEY, Sept. 16, 2021 /PRNewswire/ -- SuperTrans Medical ("STM"), a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant bacterial infections, has announced that the U.S. National Institutes of Health (NIH) will be supporting additional dev...

2021-09-16 08:45 3845

Charles Bodner Joins CSafe Global as Chief Financial Officer

CSafe Global has hired Charles Bodner as CFO following Patrick Schafer's promotion to CEO in 2020. DAYTON, Ohio, Sept. 16, 2021 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today that Charles ('Chuck') Bodner h...

2021-09-16 06:25 5773

Charles Bodner Joins CSafe Global as Chief Financial Officer

Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Become Publicly Traded on the Nasdaq via Merger with Adrian Cheng's Artisan Acquisition Corp.

* Prenetics' mission is to disrupt and decentralise the healthcare industry with a global opportunity of overUS$1.3 trillion. * Prenetics' multi-product healthcare ecosystem strategy is driven by prevention focused genomic testing, rapid diagnostics for COVID-19 and infectious diseases, and c...

2021-09-16 06:00 8731

Prenetics, a Global Leader in Genomic and Diagnostic Testing, to Become Publicly Traded on the Nasdaq via Merger with Adrian Cheng's Artisan Acquisition Corp.

* Prenetics' mission is to disrupt and decentralise the healthcare industry with a global opportunity of overUS$1.3 trillion. * Prenetics' multi-product healthcare ecosystem strategy is driven by prevention focused genomic testing, rapid diagnostics for COVID-19 and infectious diseases, and c...

2021-09-16 06:00 9679

ThinkSono DVT detection software results are published in Nature digital medicine (npj)

LONDON and POTSDAM, Germany, Sept. 15, 2021 /PRNewswire/ -- A team of researchers are developing the use of an artificial intelligence (AI) algorithm with the aim of diagnosing deep vein thrombosis (DVT) more quickly and as effectively as traditional radiologist-interpreted diagnostic scans, pot...

2021-09-15 19:34 3651

ThinkSono DVT detection software results are published in Nature digital medicine (npj)

2021 Centre for Medicines Research (CMR) Pharmaceutical R&D Factbook from Clarivate Finds Drug Approvals at a 10-year High Despite the Challenges of COVID-19

LONDON, Sept. 15, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of the2021 Centre for Medicines Research (CMR) International Pharmaceutical R&D Factbook. The 2021 CMR ...

2021-09-15 16:00 1654

Sputnik V Demonstrates 97.2% Efficacy And High Safety Profile Against COVID During The Vaccination Campaign In Belarus

MOSCOW, Sept. 15, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the real world data of the Ministry of Health of theRepublic of Belarus on the Russian Sputnik V coronavirus vaccine confirming its high efficacy during the vaccination campai...

2021-09-15 16:00 1942

US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments

MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 million in 2020. Starpharma

2021-09-15 15:27 3230

CStone received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody, marking further expansion of its Pipeline 2.0

SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational ne...

2021-09-15 08:30 3849

Peijia Medical Announces First Patient Implant in the Clinical Trial of its Third-Generation Transcatheter Aortic Valve System TaurusNXT®

SUZHOU, China, Sept. 14, 2021 /PRNewswire/ -- Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the third-generation transcatheter aortic valve ("TAVR") system, following the first successful patient implant in Zhongshan Hospital of Fudan Univers...

2021-09-14 22:11 5266

PolyU develops groundbreaking and highly effective targeted osteoarthritis pain reliever

HONG KONG, Sept. 14, 2021 /PRNewswire/ -- Researchers at The Hong Kong Polytechnic University (PolyU) have developed a groundbreaking, imaging-guided nanoparticle photothermal treatment for osteoarthritis pain, utilising the concept of targeted cancer therapy but instead applied to the protein th...

2021-09-14 20:37 2532

New Therapy to Treat Advanced Small Cell Lung Cancer Approved for Australian Patients

Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved to treat second-line metastatic SCLC inAustralia in more than 20 years * * ZEPZELCA approval granted under a provisional regulatory pathway * US FDA and TGA collaborated via 'Project Orbis' to accelerate avail...

2021-09-14 18:57 2289

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs

VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, the company's COVID-19 vaccine candida...

2021-09-14 15:00 6512

Jemincare group has completed the Phase I clinical trial of its anti-SARS-CoV-2 neutralizing antibody JMB2002

SHANGHAI, Sept. 14, 2021 /PRNewswire/ -- Recently, Jemincare group has declared that it has completed phase I clinical trial of self-developed novel coronavirus specific neutralizing antibody (Project code: JMB2002). The clinical trial of JMB2002 was stated in January 2021. A single-center, rand...

2021-09-14 11:43 4797